Based on this systematic review and meta-analysis, P2Y12 inhibitor monotherapy followed by a short duration of dual antiplatelet therapy could significantly decrease the risk of bleeding events without increasing the risk of stent thrombosis or myocardial infarction in the general population. This evidence concerns the gene P2RY12 and myocardial infarction.